Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Vectura Ltd","sponsor":"Aerami","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vectura Signs Agreement with Aerami Therapeutics Inc","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Vectura Ltd"}]

Vectura Ltd

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Contact Supplier

Contact Supplier

Digital Content

Vectura Signs Agreement with Aerami Therapeutics Inc

Details:

Aerami will be responsible for the overall development and commercialisation of inhaled imatinib, with Vectura providing development services expertise and a license to its FOX® mesh nebuliser technology.

Lead Product(s): Imatinib Mesylate

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

Highest Development Status: IND Enabling Product Type: Small molecule

Partner/Sponsor/Collaborator: Aerami

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement June 08, 2020

Skyepharma Company Banner

18th Oligonucleotide Therapeutics

Not Confirmed

envelop

Contact Supplier

POST ENQUIRY